OTCMKTS:ENDV Endonovo Therapeutics (ENDV) Stock Forecast, Price & News $0.01 0.00 (-0.67%) (As of 01:00 PM ET) Add Compare Share Share Today's Range$0.0148▼$0.014950-Day Range$0.01▼$0.019952-Week Range$0.00▼$0.03Volume13,784 shsAverage Volume353,251 shsMarket Capitalization$4.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort InterestProfileChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest About Endonovo Therapeutics (OTCMKTS:ENDV) StockEndonovo Therapeutics, Inc. is a biotechnology company, which engages in the development, manufacture, and distribution of medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, and SofPulse Electroceutical Therapy. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.Read More Receive ENDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ENDV Stock News HeadlinesMay 2, 2023 | finance.yahoo.comEndonovo Launches SofPulse® into the Veterans AdministrationApril 27, 2023 | americanbankingnews.comEndonovo Therapeutics (OTCMKTS:ENDV) Stock Price Crosses Below 50 Day Moving Average of $0.02May 31, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.April 25, 2023 | finance.yahoo.comEndonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment StudiesApril 13, 2023 | finance.yahoo.comEndonovo Announces Partnership with Former NFL Dallas Cowboy Defensive LinemanApril 10, 2023 | finance.yahoo.comEndonovo Announces Partnership with Santana Lead Singer Andy VargasMarch 29, 2023 | finance.yahoo.comEndonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off CompanyMarch 23, 2023 | finance.yahoo.comEndonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in TaiwanMay 31, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 15, 2023 | finance.yahoo.comOlympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder SurgeryMarch 9, 2023 | finance.yahoo.comEndonovo Therapeutics (OTCMKTS:ENDV) Reaches Distribution Agreement with Academy MedicalMarch 6, 2023 | finance.yahoo.comEndonovo Announces Distribution Agreement with Academy MedicalFebruary 28, 2023 | finance.yahoo.comEndonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira WeisbergJanuary 31, 2023 | finance.yahoo.comEndonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-OffJanuary 26, 2023 | finance.yahoo.comEndonovo Partners with International Distributor for SofPulse® LineJanuary 23, 2023 | reuters.comENDV.PK - | Stock Price & Latest News | ReutersJanuary 19, 2023 | finance.yahoo.comNew Details on Endonovo’s Spin-Off of SofPulse, Inc.January 9, 2023 | finance.yahoo.comEndonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public CompanyJanuary 3, 2023 | finance.yahoo.comEndonovo Targets Dept. of Defense, VA & Federal ContractsDecember 19, 2022 | finance.yahoo.comEndonovo Announces Advancement of International “Go to Market” InitiativeDecember 15, 2022 | finance.yahoo.comEndonovo Announces Plans for Spin-off of Medical IP and AssetsDecember 13, 2022 | finance.yahoo.comEndonovo Launches Telehealth InitiativeNovember 22, 2022 | markets.businessinsider.comEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational ProgressNovember 17, 2022 | finance.yahoo.comENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETSNovember 7, 2022 | finance.yahoo.comEndonovo Therapeutics Issues Corporate UpdateNovember 3, 2022 | msn.comAcrivon Therapeutics sets IPO price rangeSeptember 30, 2022 | markets.businessinsider.comEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational ProgressSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ENDV Company Calendar Today5/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ENDV CUSIPN/A CIK1528172 Webwww.endonovo.com Phone(800) 489-4774Fax818-230-9899Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,480,000.00 Net Margins-3,988.29% Pretax Margin-3,988.29% Return on EquityN/A Return on Assets-639.23% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$140,000.00 Price / Sales29.37 Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-0.17Miscellaneous Outstanding Shares276,290,000Free Float260,785,000Market Cap$4.11 million OptionableNot Optionable Beta0.25 Key ExecutivesAlan Brian CollierChairman, CEO, CFO & SecretaryDon CalabriaVice President-OperationsGarry Michael KannHead-Corporate DevelopmentIra WeisbergPresident-Medical DivisionDavid ClarkVice President-SalesKey CompetitorsHelius Medical TechnologiesNASDAQ:HSDTNuwellisNASDAQ:NUWEENDRA Life SciencesNASDAQ:NDRATivic Health SystemsNASDAQ:TIVCNon-Invasive Monitoring SystemsOTCMKTS:NIMUView All Competitors ENDV Stock - Frequently Asked Questions How have ENDV shares performed in 2023? Endonovo Therapeutics' stock was trading at $0.0180 at the beginning of the year. Since then, ENDV shares have decreased by 17.3% and is now trading at $0.0149. View the best growth stocks for 2023 here. What other stocks do shareholders of Endonovo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Ekso Bionics (EKSO), Geron (GERN), Marinus Pharmaceuticals (MRNS), Micron Technology (MU), Novavax (NVAX) and Exxon Mobil (XOM). What is Endonovo Therapeutics' stock symbol? Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV." How do I buy shares of Endonovo Therapeutics? Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Endonovo Therapeutics' stock price today? One share of ENDV stock can currently be purchased for approximately $0.01. How much money does Endonovo Therapeutics make? Endonovo Therapeutics (OTCMKTS:ENDV) has a market capitalization of $4.11 million and generates $140,000.00 in revenue each year. How can I contact Endonovo Therapeutics? Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The official website for the company is www.endonovo.com. The biotechnology company can be reached via phone at (800) 489-4774, via email at sbarnes@endonovo.com, or via fax at 818-230-9899. This page (OTCMKTS:ENDV) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endonovo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.